
Hunter Land
Dr. Hunter Land, PhD, MS, has a deep knowledge of cannabinoid science spanning over two decades of research and development across 25 therapeutic areas. He has dedicated 12 years to advancing cannabinoid research, notably overseeing large scale R&D projects that contributed to the FDA approval of Epidiolex—the first plant-derived cannabinoid medication approved by the FDA. Currently serving as CEO of Lupvindol Bioscience, Dr. Land guides a team of seasoned professionals in the rapid development of innovative, patent-protected medicines aimed at addressing critical unmet medical needs. His pioneering work and commitment to improving human and animal health continues to shape the future of cannabinoid-based therapeutics. At BRC, one of the select DEA Schedule I, FDA-compliant cannabinoid research companies, Dr. Land initiated four FDA-approved Investigational New Drug (IND) applications with cannabinoid based therapeutics. His previous roles include serving as Senior Scientific Director and Director of Cannabinoid Research at Canopy Growth Corporation, previously the world's largest cannabis producer, and as GW Pharma's first full-time R&D employee in the US, where he was instrumental in developing Epidiolex® and Sativex® including co-authorship of protocols for treating refractory epilepsy, multiple sclerosis, and pain. Dr. Land's contributions to the field are widely recognized. He has presented at over 50 scientific conferences, is a named inventor on nine patent applications, and has authored more than 20 publications. He is a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a leading cannabinoid expert. In addition to his primary roles, Dr. Land holds several prestigious positions: Chief Scientific Officer of the National Hockey League Alumni/NEEKA Brain Health, Scientific Advisory Board Member at Nalu Biosciences, Veterinary Cannabis Society, CannMed, and the Council for Federal Cannabis Regulation, Co-founder of the Cannabinoid Education Working Group, Previous Executive Board Member at Alterola Biotech. Dr. Land's knowledge in cannabinoid research, drug development, and regulatory processes positions him as an invaluable asset in the advancement of cannabis-based therapeutics
Recent Comments